# TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer

> **NCT03732235** · — · UNKNOWN · sponsor: **Giammaria Fiorentini** · enrollment: 50 (estimated)

## Conditions studied

- Liver Metastasis Colon Cancer

## Interventions

- **DEVICE:** TACE+ systemic Bevacizumab
- **DRUG:** FOLFIRI+Bevacizumab
- **DEVICE:** TACE

## Key facts

- **NCT ID:** NCT03732235
- **Lead sponsor:** Giammaria Fiorentini
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2021-10
- **Final completion:** 2021-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732235, "TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03732235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*